Learn more →
Back to Expert Scholars
Translational Medicine / 转化医学Anti-Angiogenic Therapy, Renal Cell Carcinoma

Robert Bhatt

MD, PhD

🏢Beth Israel Deaconess Medical Center / Harvard Medical School🌐USA

Associate Professor of Medicine

28
h-index
0
Key Papers
0
Key Contributions

👥Biography 个人简介

Dr. Robert Bhatt is a GU oncologist at BIDMC specializing in renal cell carcinoma anti-angiogenic therapy. He has contributed to translational analyses of VEGFR inhibitor efficacy and resistance in clear-cell RCC and studied biomarkers predicting response to sunitinib, pazopanib, and cabozantinib. His research examines adaptive resistance mechanisms to VEGF pathway inhibition that lead to TKI failure in RCC.

Share:

🧪Research Fields 研究领域

anti-angiogenic therapy renal cell carcinoma
VEGFR TKI kidney cancer
sunitinib pazopanib cabozantinib
angiogenesis biomarkers RCC
anti-VEGF resistance mechanisms RCC

🎓Key Contributions 主要贡献

Representative Works 代表性著作

📄Data Sources 数据来源

Last updated: 2026-04-01 | All information from publicly available academic sources

关注 Robert Bhatt 的研究动态

Follow Robert Bhatt's research updates

留下邮箱,当我们发布与 Robert Bhatt(Beth Israel Deaconess Medical Center / Harvard Medical School)相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment